29838-67-3
基本信息
落婦新苷
落新婦苷對(duì)照品,
落新婦苷(標(biāo)準(zhǔn)品)
落新婦苷(落新婦甙)
落新婦苷(分析標(biāo)準(zhǔn)品)
落新婦苷, 來源于土茯苓
紫杉葉3-O鼠李甲基酸酯
ASTILBIN 落新婦苷
ASTILBIN 落新婦苷 標(biāo)準(zhǔn)品
Taxifolin 3-rhaMnoside
Taxifolin 3-o-rhamnoside
Dihydroquercetin 3-rhamnoside
Astilbin Taxifolin 3-O-rhaMnoside
Astilbin, 98%, from Smilax glabra Roxb.
Astilbin froM Engelhardtia roxburghiana
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-3,4-dihydro-2H-chroMen-3-yl 6-deoxy-alpha-L-Mannopyranoside
(2R,3R)-3-[(6-Deoxy-alpha-L-mannopyranosyloxy)]-2-(3,4-dihydroxy-phenyl)-2,3-dihydro-5,7-dihydroxy-4H-chromen-4-one
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy-chroman-4-one
物理化學(xué)性質(zhì)
常見問題列表
土茯苓為百合科植物光葉菝鍥(Smilax glabra Roxb.)的干燥根莖,它是一種常用中藥材,具有除濕,解毒通利關(guān)節(jié)的作用。 紫杉葉3-O鼠李甲基酸酯(astilbin)是土茯苓中分離得到的一種黃酮類化合物,具有殺蟲,抑制輔酶A還原酶,抑制醛糖還原酶,保肝,鎮(zhèn)痛,抗水腫,抗氧化等活性作用。
紫杉葉3-O鼠李甲基酸酯還能顯著改善免疫性肝損傷,誘導(dǎo)PHA活化的Jurkat細(xì)胞凋亡,通過抑制活化T淋巴細(xì)胞的功能來抑制遲發(fā)型超敏反應(yīng)和治療小鼠膠原型關(guān)節(jié)炎等。
TNF-α
|
NF-κB
|
NRF2
|
Astilbin is a common dietary flavonoid that can be found in various kinds of herbs and foods such as Smilax Glabra , Sarcandra glabra , grape and red wine. Astilbin markedly inhibits cisplatin-induced cell apoptosis and recovers cell growth. Astilbin significantly decreases reactive oxygen species (ROS) accumulation and alleviates ROS-induced activation of p53, MAPKs and AKT signaling cascades, which in turn attenuates cisplatin-induced HEK-293 cell apoptosis. Astilbin effectively enhances NRF2 activation and transcription of its targeting antioxidant genes to reduce ROS accumulation in cisplatin-induced HEK-293 cells. Astilbin obviously suppresses tumor necrosis factor alpha (TNF-α) expression and NF-κB activation, and also inhibits the expression of induced nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). To measure the effects of Astilbin on the growth of CDDP-treated renal cells, HEK-293 cells are treated with CDDP (100 μM) and/or Astilbin (200 μM). Astilbin treatment significantly improvescell growth in CDDP-induced HEK-293 cells.
To explore whether Astilbin improves CDDP-induced nephrotoxicity in vivo, an acute cisplatin nephrotoxic mouse model is established. Single injection of CDDP with 8 mg/kg dose results in notable weight loss compared with control group. However, the phenomenon is significantly alleviated by Astilbin at dose of 50 mg/kg. The mice fed Astilbin alone do not show any obvious alteration in body weight. Similarly, serum creatinine (SCr) and blood urea nitrogen (BUN) are higher in CDDP-treated mice than in control group. Treatment with Astilbin also decreases SCr and BUN levels. To examine the protective effect of Astilbin on CDDP-induced renal histopathological damage, the mouse kidney sections are stained with H&E. The mice in control group and Astilbin treated group have normal kidney morphology, while kidneys in CDDP group show severe damage with tubular degeneration, necrosis and cystic dilatation of the tubules with focal hemorrhages. Administration of Astilbin mitigated kidney injury, resulting in lower histopathological score compared to CDDP group. The apoptosis of renal cells is also detected using TUNEL staining to determine whether Astilbin treatment decreased renal cell apoptosis in CDDP-induced acute nephrotoxic mice.